Cagrilintide
Also known as AM833
Cagrilintide is an investigational long-acting amylin receptor agonist studied both alone and in combination with GLP-1 agonists for weight management. As monotherapy, trials have reported meaningful but generally more modest average weight reduction than the leading combination and multi-agonist therapies. It has not received independent regulatory approval and is most often studied as part of combination products such as CagriSema. Evidence for cagrilintide as a standalone therapy remains more limited than for combination use.
Reported benefits
- Associated with meaningful average weight loss as monotherapy in trials
- Once-weekly dosing schedule
- Complementary satiety mechanism to GLP-1 agonists
- Studied as a component of combination therapies with additive effects reported
How it works
Cagrilintide activates amylin receptors, mimicking the pancreatic hormone amylin, which slows gastric emptying and contributes to satiety signaling in the brain. Its long-acting formulation is designed to support once-weekly dosing, and its mechanism is complementary to but distinct from GLP-1 receptor agonism.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 0.3 mg | once weekly |
| Moderate | 2.4 mg | once weekly |
| High | 4.5 mg | once weekly |
Estimate your dose
Dose estimator
Educational estimate for Cagrilintide, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Cagrilintide. Educational only.
Draw to this mark
48units
= 0.48 mL for a 2.4 mg dose
Concentration
5 mg/mL
Doses per vial
4
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Most commonly studied in combination with GLP-1 receptor agonists (e.g., semaglutide); such combinations should only occur under medical supervision or within trial protocols.
Common protocols
Common questions
What is Cagrilintide used for?
Cagrilintide is an investigational long-acting amylin receptor agonist studied both alone and in combination with GLP-1 agonists for weight management. As monotherapy, trials have reported meaningful but generally more modest average weight reduction than the leading combination and multi-agonist therapies. It has not received independent regulatory approval and is most often studied as part of combination products such as CagriSema. Evidence for cagrilintide as a standalone therapy remains more limited than for combination use. Reported benefits include associated with meaningful average weight loss as monotherapy in trials, once-weekly dosing schedule, complementary satiety mechanism to glp-1 agonists.
What is a typical Cagrilintide dose?
Reported ranges run 0.3-4.5 mg. A low protocol is 0.3 mg once weekly, and a high protocol is 4.5 mg once weekly. This is reference information, not a dosing recommendation.
What is the half life of Cagrilintide?
Approximately 7 days, consistent with once-weekly dosing. That is what sets the dosing frequency, and it is why the timing guidance is weekly · same day, any time.
How is Cagrilintide administered?
Subcutaneous: into fat, under the skin.
How long is a Cagrilintide cycle?
Continuous use with titration over several months in trial protocols on, followed by Not established outside of trial settings off.
What are the side effects of Cagrilintide?
Reported side effects include nausea, vomiting, and diarrhea, especially during titration, decreased appetite, injection-site reactions, long-term monotherapy safety data remain limited. Evidence level for this compound is moderate evidence.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Cagrilintide may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →